Unknown

Dataset Information

0

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma.


ABSTRACT: Patient-derived tumor xenograft (PDTX) mouse models were used to discover new therapies for naïve and drug resistant BRAFV600E -mutant melanoma. Tumor histology, oncogenic protein expression, and antitumor activity were comparable between patient and PDTX-matched models thereby validating PDTXs as predictive preclinical models of therapeutic response in patients. PDTX models responsive and non-responsive to BRAF/MEK standard of care (SOC) therapy were used to identify efficacious combination therapies. One such combination includes a CDK4/6 inhibitor that blocks cell cycle progression. The rationale for this is that the retinoblastoma protein (pRb) is 95% wildtype in BRAF mutant melanoma. We discovered that 77/77 stage IV metastatic melanoma tissues were positive for inactive phosphorylated pRb (pRb-Ser780). Rb is hyperphosphorylated and inactivated by CDK4/6:cyclin D1 and when restored to its hypophosphorylated active form blocks cell cycle progression. The addition of a CDK4/6 inhibitor to SOC therapy was superior to SOC. Importantly, triple therapy in an upfront treatment and salvage therapy setting provided sustained durable response. We also showed that CDK4/6 blockade resensitized drug resistant melanoma to SOC therapy. Durable response was associated with sustained suppression of pRb-Ser780. Thus, reactivation of pRb may prove to be a clinical biomarker of response and the mechanism responsible for durable response. In light of recent clinical trial data using this triple therapy against BRAFV600E -mutant melanoma, our findings demonstrating superior and prolonged durable response in PDTX models portend use of this therapeutic strategy against naïve and SOC resistant BRAFV600E -mutant metastatic melanoma coupled with pRB-Ser780 as a biomarker of response.

SUBMITTER: Harris AL 

PROVIDER: S-EPMC5834273 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF <sup><i>V600E</i></sup> -mutant melanoma.

Harris Antoneicka L AL   Lee Samantha E SE   Dawson Louis K LK   Marlow Laura A LA   Edenfield Brandy H BH   Durham William F WF   Flotte Thomas J TJ   Thompson Michael M   Small Daniel L DL   Synnott Aidan J AJ   Markovic Svetomir N SN   Copland John A JA  

Oncotarget 20171223 13


Patient-derived tumor xenograft (PDTX) mouse models were used to discover new therapies for naïve and drug resistant <i>BRAF</i><sup><i>V600E</i></sup> -mutant melanoma. Tumor histology, oncogenic protein expression, and antitumor activity were comparable between patient and PDTX-matched models thereby validating PDTXs as predictive preclinical models of therapeutic response in patients. PDTX models responsive and non-responsive to BRAF/MEK standard of care (SOC) therapy were used to identify ef  ...[more]

Similar Datasets

| S-EPMC10176035 | biostudies-literature
| S-EPMC4001781 | biostudies-literature
| S-EPMC6195480 | biostudies-literature
| S-EPMC7449901 | biostudies-literature
| S-EPMC3590666 | biostudies-other
| S-EPMC8445818 | biostudies-literature
| S-EPMC7141227 | biostudies-literature
| S-EPMC5679278 | biostudies-literature
| S-EPMC10060292 | biostudies-literature
| S-EPMC4929150 | biostudies-literature